Health-related quality of life and utilities in gastric premalignant conditions and malignant lesions: a multicentre study in a high prevalence country by Areia, M. et al.
J Gastrointestin Liver Dis, December 2014 Vol. 23 No 4: 371-378
1) Center for Research in 
Health Technologies and 
Information Systems, Faculty 
of Medicine, Porto University; 
2) Gastroenterology Dept., 
Portuguese Oncology 
Institute of Coimbra; 3) 
Gastroenterology Dept., 
Portuguese Oncology Institute 
of Lisbon; 4) Gastroenterology 
Dept., Santa Luzia Hospital 
- Viana do Castelo (Local 
Health Unit of Alto Minho);  5) 
Gastroenterology Dept., Santo 
António General Hospital, 
Hospital Centre of Porto;  6) 
Institute of Biomedical Sciences 
Abel Salazar,University of 
Porto; 7) Gastroenterology 
Dept., Hospital Unit of 
Portimão (Hospital Center 
of Western Algarve); 8) 
Gastroenterology Dept., 
Coimbra University Hospital 
Center; 9) Gastroenterology 
Dept., Portuguese Oncology 
Institute of Porto; 10) 
Gastroenterology Dept., 
West Lisbon Hospital Centre, 
Lisbon, Portugal
Address for correspondence: 
Miguel Areia
Gastroenterology Department 
Portuguese Oncology Institute 
Coimbra, Portugal
miguel.areia75@gmail.com
Received: 25.07.2014     
Accepted: 08.09.2014
Health-related Quality of Life and Utilities in Gastric 
Premalignant Conditions and Malignant Lesions: a Multicentre 
Study in a High Prevalence Country 
Miguel Areia1,2, Susana Alves2, Daniel Brito2, Ana Teresa Cadime2, Rita Carvalho2, Sandra Saraiva2, Sara Ferreira3, Joana 
Moleiro3, António Dias Pereira3, João Carrasquinho4, Luís Lopes4, José Ramada4, Ricardo Marcos-Pinto1,5,6, Isabel Pedroto5,6, 
Luís Contente7, Liliana Eliseu7, Ana Margarida Vieira7, Margarida Sampaio7, Helena Tavares Sousa7, Nuno Almeida8, Carlos 
Gregório8, Francisco Portela8, Carlos Soa8, Vânia Braga9, Elisabete Baginha10, Tiago Bana e Costa10, Cristina Chagas10, 
Luís Lebre Mendes10, Pedro Magalhães-Costa10, Leopoldo Matos10, Francisco Rocha Gonçalves1,9, Mário Dinis-Ribeiro1,9
INTRODUCTION
Gastric adenocarcinoma is 
a health problem worldwide 
due to its high incidence and 
mortality rates, being the fourth 
most common malignancy and 
the second leading cause of 
cancer death [1]. Its prognosis 
is highly dependent on the stage 
at diagnosis but usually presents 
at an advanced stage requiring 
demanding treatments and costs 
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ABSTRACT
Background & Aims: A recent review of economic studies relating to gastric cancer revealed that authors use 
dierent tests to estimate utilities in patients with and without gastric cancer. Our aim was to determine the 
utilities of gastric premalignant conditions and adenocarcinoma with a single standardized health measure 
instrument.
Methods: Cross-sectional nationwide study of patients undergoing upper endoscopy (n=1,434) using the 
EQ-5D-5L quality of life (QoL) questionnaire.
Results: According to EQ-5D-5L, utilities in individuals without gastric lesions were 0.78 (95% condence 
interval: 0.76-0.80), with gastric premalignant conditions 0.79 (0.77-0.81), previously treated for gastric cancer 
0.77 (0.73-0.81) and with present cancer 0.68 (0.55-0.81). Self-reported QoL according to the visual analogue 
scale (VAS) for the same groups were 0.67 (0.66-0.69), 0.67 (0.66-0.69), 0.62 (0.59-0.65) and 0.62 (0.54-0.70) 
respectively. Utilities were consistently lower in women versus men (no lesions 0.71 vs. 0.78; premalignant 
conditions 0.70 vs. 0.82; treated for cancer 0.72 vs. 0.78 and present cancer 0.66 vs. 0.70).
Conclusion: e health-related QoL utilities of patients with premalignant conditions are similar to those 
without gastric diseases whereas patients with present cancer show decreased utilities. Moreover, women had 
consistently lower utilities than men. ese results conrm that the use of a single standardized instrument 
such as the EQ-5D-5L for all stages of the gastric carcinogenesis cascade is feasible and that it captures 
dierences between conditions and gender dissimilarities, being relevant information for authors pretending 
to conduct further cost-utility analysis.
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and impairing quality of life (QoL), even for patients with a 
good prognosis [2].
In health economics studies, the clinical strategies 
adopted for a problem such as gastric cancer are compared by 
simultaneously addressing their dierences in terms of both 
clinical benets and the cost of achieving them [3]. Guidelines 
recommend conducting cost-utility analysis where the use of 
clinical benets should be adjusted to patient preferences. us, 
life-years saved (LYS) may be adjusted to utilities in terms of 
QoL, quality adjusted life years (QALYs), meaning that 1 year 
of life is multiplied by a utility factor between 1 and 0, providing 
dierent values for each single year of life, resulting in an utility 
value that will vary between 1 QALY (one year with perfect 
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QoL) and 0 (death, by denition). ese guidelines also suggest 
that community preferences should be used instead of patient 
preferences [4-6].
In a recent systematic review of the literature on economic 
studies relating to gastric cancer our group found that authors 
mostly used patient preferences instead of the recommended 
community preferences and that utilities were obtained 
by using several measurement instruments, including 
questionnaires that were specically created for comparing 
gastric cancer treatments that should not be compared to 
utilities in the general population. Also, models tend to 
use utilities reported in other studies, usually conducted in 
countries dierent from the population in the model, where 
health valuations might have given dierent results [7]. Utilities 
obtained in a population with a single questionnaire could 
be very suitable for conducting cost-utility analysis on the 
gastric cancer problem since they would provide comparative 
utilities for all stages of the gastric cancer cascade from an 
asymptomatic population to gastric cancer patients [8].
us, the aim of our study was to perform a cross-sectional 
study to obtain utilities from a population that would include 
patients without gastric lesions and also with all kinds of 
upper gastrointestinal diseases, including patients with all 
ranges of gastric premalignant conditions, patients submitted 
to endoscopic treatments and patients with gastric cancer 
submitted to all available treatments [9-11].
METHODS
is cross-sectional study was performed in 8 Portuguese 
hospitals over 6 months, between 2012 and 2013, by delivering 
a QoL related questionnaire to patients already scheduled for 
routine upper gastrointestinal endoscopic examinations. e 
questionnaire was the Portuguese version of the EQ-5D-5L and 
the reference test for the diagnosis was the gastroenterology 
diagnosis, including the histopathology result when applicable. 
The planning, development and report of the study are 
in accordance with the STROBE statement for reports on 
observational studies [12, 13].
Portugal is considered to have a high-incidence of 
gastric cancer according to the GLOBOCAN denition by 
presenting an age-standardized incidence rate of 13.7 per 
100,000 [14]. From all over the country, including north, 
centre, south of Portugal and the two major cities of Lisbon 
and Porto, 8 gastroenterology departments in 8 dierent 
hospitals comprising 2 academic hospitals, 3 oncology 
centers and 3 regional hospitals, were invited and agreed 
to participate. Consecutive patients were included in each 
hospital for 3 months and each patient scheduled for an upper 
endoscopy procedure was invited to complete a questionnaire 
before the examination to self-report their QoL on the day 
of the examination.
e outcomes obtained were the self-reported answers 
to the questionnaire, providing a measure of QoL on the 
day of the upper endoscopy procedure, plus the diagnosis 
provided by the attending gastroenterologist, which can be 
based on the endoscopic diagnosis, pathology result or known 
medical history, as applicable. To allow for generalization of 
results, a selection of hospitals was made in order to obtain a 
heterogeneous population in terms of both geographic location 
and hospital setting.
e only inclusion criteria were the completion of an 
already scheduled upper endoscopy along with a voluntary 
signed informed consent specic to the study. Exclusion criteria 
were emergency examinations, failure to provide informed 
consent or any contraindication for upper endoscopy. 
e study was approved by the Portuguese Data Protection 
Authority (Authorization 4982/2012) aer granting permission 
for the compilation of multicenter national data, and also by 
each hospital Ethics Committee. Condentiality of all records 
was ensured by removing the names of patients, doctors and 
nurses from the reports before they were sent to the main 
investigator. 
Selection bias was minimized by asking all institutions for 
a consecutive sample, having a very broad inclusion criteria 
setting and carrying out the study in the whole country in 
hospitals with very dierent population characteristics, for at 
least 3 months in order to allow the inclusion of most types of 
upper gastrointestinal diseases.
QoL questionnaire
The questionnaire used was the EQ-5D-5L developed 
by the EuroQol Group, which is a standardized measure to 
provide utilities for clinical and economic appraisal [15]. is 
questionnaire was chosen because it can be applied to a wide 
range of health conditions and treatments, provides a simple 
descriptive prole and a single index value for each health 
status, has been validated over many years in a number of 
populations and settings, is the most recent version of the 
EuroQol EQ-5D questionnaire and is available in several 
translations, including an already validated and reliable 
Portuguese version  [16]. 
The EQ-5D-5L questionnaire comprises a descriptive 
system and a visual analogue scale (VAS). e descriptive 
system has 5 dimensions: mobility, self care, usual activities, 
pain/discomfort and anxiety/depression, and each dimension 
has 5 levels: no problems, slight problems, moderate problems, 
severe problems, and extreme problems (the former EQ-5D 
had only 3 choices per question, being called EQ-5D-3L). 
Respondents are asked to indicate their health state by marking 
the box against the most appropriate statement in each of the 5 
dimensions. e digits for the 5 dimensions can be combined 
in a 5-digit number describing the respondent’s health state. 
Health states dened by the EQ-5D-5L descriptive system 
were converted into a single index value to calculate utilities, 
according to the recommendations of the EuroQol Group [17].
e similar EQ-5D-3L system was only recently validated 
in the Portuguese population, by setting preferences for the 
general population using the time trade-o technique and also 
developing population norms [18, 19]. Because currently there 
is no validated method to transform utilities from the EQ-5D-
3L to the EQ-5D-5L systems, we used the Spanish EQ-5D-5L 
utilities. From the available options, the Spanish utilities are 
the most similar, providing a Pearson’s correlation coecient 
of r=0.946 for both EQ-5D-3L population norms [18]. 
e VAS records the respondent’s self-rated health on a 20 
cm vertical VAS, with endpoints labeled “the best health you 
can imagine” and “the worst health you can imagine”.
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A correctly completed questionnaire was dened as a 
questionnaire with each of the 5 multiple choice questions for 
the descriptive system completed with a single cross and a clear 
and readable number in the VAS.
Endoscopic procedure
For each questionnaire the corresponding diagnosis was 
obtained from the upper endoscopy result. Upper endoscopy 
is considered the ideal procedure for the diagnosis of upper 
gastrointestinal diseases due to its widespread availability, 
improved accuracy for most diseases, relatively minor 
invasiveness and possibility of performing diagnostic and/
or therapeutic procedures [20-24]. ere were no specic 
inclusion or exclusion criteria based on patient diagnosis, 
endoscopists’ experience, type of endoscopic facility or scope. 
Biopsies were done as deemed necessary, but not specically 
for participation in the study.
Sample size and statistical analysis
For the sample size calculation, an estimate of at least 44 
patients per group would be needed for a level of signicance 
of 0.05 and a power of 0.80, based on previous reports that for 
normal patients the utility score was 0.90, for patients with 
premalignant conditions 0.70 and for patients with gastric 
cancer 0.50. We aimed at obtaining 100 patients for each of 
these groups, to ensure that condence intervals would not be 
wider than ±0.10, in order to achieve statistically signicant 
dierences between utilities [25].
Results are reported as means and 95% condence interval 
(CI) for continuous variables and percentages for proportions. 
For comparative analysis the Student’s t-test was used for 
continuous variables according to their normal distribution 
and the Pearson chi-square test for dichotomous variables. 
A two-sided p value <0.05 was considered to be statistically 
signicant. Results were analyzed in subgroups for confounding 
factors such as age or gender but not for co-morbidities. No 
data was missing from the retrieved questionnaires.
RESULTS
All subjects scheduled for an upper endoscopy were invited 
and aer exclusions for several factors such as refusing to 
Table I. Main patient characteristics and utilities according to stages of the gastric carcinogenesis cascade 
and most relevant upper gastrointestinal diseases
n (%) EQ-5D-5L mean 
(95% CI)
VAS mean 
(95% CI)
Patients 1,434
Male gender 755 (52.6)
Age ≥ 50 years 1,063 (74.1)
Participating hospital: n (% global), (% gastric cancer)
Portuguese Oncology Institute of Coimbra 353 (24.6), (20.7)
Portuguese Oncology Institute of Lisbon 294 (20.5), (9.5)
Santa Luzia Hospital, Viana do Castelo 205 (14.3), (4.4)
Santo António General Hospital, Porto 168 (11.7), (1.8)
Hospital Unit of Portimão 142 (9.9), (4.9)
Coimbra’s University and Hospital Center 134 (9.3), (8.9)
Portuguese Oncology Institute of Porto 69 (4.8), (20.3)
West Lisbon Hospital Centre 69 (4.8), (2.9)
No gastric lesions 678 (47.3) 0.78 (0.76-0.80) 0.67 (0.66-0.69)
Gastric premalignant conditions 
(gastritis, atrophy, intestinal metaplasia)
391 (27.3) 0.79 (0.77-0.81) 0.67(0.66-0.69)
Gastric adenocarcinoma 148 (10.3) 0.77 (0.73-0.81) 0.62 (0.59-0.65)
Treated by:
- Mucosectomy 17 (1.2) 0.78 (0.63-0.92) 0.62 (0.54-0.70)
- Surgery 69 (4.8) 0.77 (0.71-0.82) 0.62 (0.57-0.67)
- Chemo/Radiotherapy 38 (2.6) 0.83 (0.77-0.89) 0.63 (0.57-0.70)
Present carcinoma 24 (1.7) 0.68 (0.55-0.81) 0.62 (0.54-0.70)
Other lesions* 731
Hiatal hernia 155 (10.8) 0.77 (0.73-0.80) 0.66 (0.63-0.69)
Esophagitis 83 (5.8) 0.79 (0.74-0.74) 0.69 (0.65-0.73)
Peptic ulcer 36 (2.5) 0.78 (0.72-0.84) 0.62 (0.56-0.69)
Barrett’s esophagus 28 (1.9) 0.79 (0.67-0.90) 0.74 (0.66-0.80)
*Other lesions stand for all lesions in the esophagus, stomach or duodenum except for gastric premalignant 
conditions or gastric adenocarcinoma. Only the most frequent reported are presented.
Legend: EQ-5D-5L: EuroQol EQ-5D-5L questionnaire; VAS scale: visual analogue scale of the EQ-5D-5L 
questionnaire; CI: condence interval.
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participate, endoscopy not performed, declined to complete 
questionnaire or incomplete data, 1,434 questionnaires out 
of 1,886 were completed correctly achieving a participation 
rate of 76%. e characteristics of patients with incomplete 
questionnaires were not possible to access because in most 
cases the main data missing were the clinical issues such as 
age, gender or diagnosis and not the fullling of the EQ-5D-
5L questionnaire.
e main patient characteristics and results for the most 
relevant upper gastrointestinal diseases, including all stages 
of the gastric carcinogenesis cascade, are reported in Table I. 
Participants were 53% male with a mean age of 59 years. e 
examination was considered normal in only 24% of cases, and 
most relevant abnormalities detected were gastric premalignant 
conditions such as gastritis, atrophy or intestinal metaplasia 
and esophageal conditions such as hiatal hernia or esophagitis. 
There were no relevant differences between participating 
institutions in terms of patients’ diseases, except for there being 
more cancer patients in the Oncology Centers, as expected 
(13.7% vs. 4.7%, p=0.01).
In terms of the 5 dimensions of the EQ-5D-5L questionnaire, 
75% to 93% of participants said they had no or only slight 
problems in all ve dimensions with better score for self-care 
such as washing or dressing themselves and only 2.2% to 
6.1% reported severe to extreme problems with worst score 
for usual activities such as work, study, housework, family or 
leisure. Anxiety was moderate to extreme in 21% of patients 
without relevant dierences among groups (no lesions 21%, 
premalignant conditions 23%, gastric cancer 18%).
Although the numbers of included questionnaires vary 
and are related to a diverse prevalence of these diseases in 
the general population, VAS scores were consistently lower 
than the EQ-5D-5L utilities, regardless of organ or severity of 
disease, in all conditions analyzed.
Utilities for all stages of the gastric cancer cascade of 
carcinogenesis, with subgroup analysis by gender and including 
only patients aged 50 or over are summarized in Table II. 
is subgroup analysis is justied by the fact that this is the 
population (≥50 years) which is usually considered  to be cost-
eective to oer endoscopic screening or surveillance strategies 
[26]. No comparison between <50 and ≥50 years was made due 
to the huge dierences between groups in terms of available 
questionnaires 371 vs. 1063 and gastric cancer cases 11 vs. 137.
Overall scores demonstrated that the two scales provided 
similar results for patients without gastric lesions or with 
gastric premalignant conditions with utilities lower for patients 
who had present gastric cancer than for patients without gastric 
lesions or those with premalignant conditions (0.68 versus 
≥0.77, p=0.09).
When adjusting for gender and including only patients 
aged 50 or above, the results consistently show that utilities 
were lower for women than for men. is dissimilar scoring for 
males and females achieves a statistically signicant dierence 
in some normal or premalignant conditions in both scales.
DISCUSSION
is cross-sectional study of patients scheduled for an 
upper endoscopy procedure provided utilities and self-
reported QoL data for a nationwide population with a validated 
questionnaire in a sample of patients embracing all stages of 
the carcinogenic cascade for gastric adenocarcinoma. ese 
results, although specic to the studied population, might be 
relevant to further cost-utility studies in gastric cancer as a 
recent systematic review showed that utilities were relevant in 
several studies for the nal results of the economic analysis, 
namely QoL in diseased patients and also aer treatments for 
cancer [7, 8].
Utilities measured by the EQ-5D-5L questionnaire showed 
similar scores for patients without gastric lesions (0.78), 
patients with premalignant conditions (0.82) and patients with 
previously treated gastric cancer (0.77-0.79) but lower values 
Table II. Utilities according to stages of the gastric carcinogenesis cascade in patients aged 50 or over, by gender
Age ≥ 50 years p Age ≥ 50 years p
Scale EQ-5D-5L mean (95% CI) VAS mean (95% CI)
Gender Male Female Male Female
No gastric lesions 0.78 
(0.76-0.81)
0.71 
(0.67-0.75)
0.01 0.65 
(0.63-0.68)
0.63 
(0.60-0.66)
0.19
Gastric premalignant conditions 0.82 
(0.79-0.85)
0.70 
(0.66-0.74)
0.01 0.69 
(0.66-0.73)
0.60 
(0.57-0.63)
0.01
Gastric adenocarcinoma 0.78 
(0.73-0.83)
0.72 
(0.65-0.79)
0.15 0.62 
(0.58-0.67)
0.59 
(0.54-0.64)
0.33
Treated by:
 Mucosectomy 0.77 
(0.50-1.00)
0.70 
(0.33-1.00)
0.69 0.61 
(0.48-0.73)
0.52 
(0.42-0.62)
0.25
 Surgery 0.79 
(0.72-0.87)
0.71 
(0.62-0.80)
0.18 0.63 
(0.55-0.70)
0.58 
(0.51-0.66)
0.42
Chemo/Radiotherapy 0.85 
(0.79-0.91)
0.76 
(0.60-0.92)
0.19 0.64 
(0.55-0.72)
0.60 
(0.50-0.70)
0.59
Present carcinoma 0.70 
(0.42-0.97)
0.66 
(0.49-0.83)
0.79 0.66 
(0.48-0.84)
0.60 
(0.50-0.71)
0.52
Legend: EQ-5D-5L: EuroQol EQ-5D-5L questionnaire; VAS: visual analogue scale of the EQ-5D-5L questionnaire; 
CI: condence interval; *: Student’s t-test.
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for patients with present carcinoma (0.66) and for the same 
clinical situations the EQ-5D-5L scores were always lower for 
female than for male.
To the best of our knowledge this study is the first 
providing utilities for all stages of the gastric cancer cascade 
using a single health utilities measurement instrument. e 
study provides very useful information for authors conducting 
cost-utility analysis by incorporating utilities in their Markov 
models [8].
Our main conclusion and contribution to the actual medical 
practice is that the use of a single standardized instrument like 
EQ-5D-5L for all stages of disease is feasible, that it captures 
differences among stages (no lesions vs. premalignant 
conditions vs. present cancer) and adjustments by gender are 
relevant when incorporating utilities in economic models.
A second relevant conclusion is that the utilities varied 
between dierent stages of disease in a much narrower set 
of values (around 0.6 for cancer vs. 0.8 for no cancer) than 
previously reported in other models (around 0.3 vs. 0.9 for 
the same groups), raising the concern that utilities valuation 
by using dierent questionnaires for dierent stages of disease, 
as has been done in other models, might overvalue real 
dierences and overestimate the nal economic conclusions 
among strategies.
Table III. Comparison of the current study with published cost-utility studies on gastric cancer and respective references used for utilities valuation
Present study 1. Values for the asymptomatic population
2. Normal is dierent from 1
3. Values for all gastric premalignant conditions (gastritis, atrophy, intestinal metaplasia and dysplasia)
4. Values for endoscopic treatment (mucosectomy)
5. Values for gastric cancer patients in 3 dierent stages of treatment (surgery, chemotherapy and/or radiotherapy and 
best supportive care)
6. Dierent evaluations for men and women
Other studies 
(1st author, year, country)
Intervention Utilities references Utility values from references Comment on references used
Xie, 2008 [31]
Xie, 2008 [32] 
Singapore
Screening (serology) 
and treat H. pylori or 
Screening (UBT) and 
treat H. pylori
Wang Q, et al. 2003 [38] H. pylori non-infected 1.00 
(0.95-1.00) 
H. pylori infected 0.90 (0.80-
1.00) 
Gastric cancer 0.38 (0.13-0.65)
Normal is 1 
No values for population 
No values for premalignant 
gastric conditions 
Just one value for gastric cancer
Xie, 2009 [33] 
Canada
Screening (Stool Ag) or 
Screening (serology) or 
Screening (UBT†)
Delaney BC, et al. 2008 [39] 
Ajani JA, et al. 2007 [40]
H. pylori uninfected 0.83 
(0.80-0.86) 
H. pylori infected 0.83 (0.80-
0.86) 
Gastric cancer 0.55 (0.47-0.63)
No values for population 
No values for premalignant 
gastric conditions 
Same value for uninfected and 
infected patients Just one value 
for gastric cancer
Yeh, 2009 [37] 
China
Screening (serology) 
and treat H. pylori or 
Universal treatment
Mathers CD, et al. 2000 [41] 
Gold MR, et al. 1998 [25]
Normal gastric mucosa 
0.56–0.94 
Gastritis 0.56–0.94 
Atrophy 0.56–0.94 
Intestinal metaplasia 0.56–0.94 
Dysplasia 0.56–0.94 
Symptomatic gastric cancer 
0.49 (0.17–0.79)
No values for population 
Same value for all premalignant 
lesions Just one value for gastric 
cancer
Dan, 2006 [35] 
Singapore
Endoscopy every 2 
years
Glimelius B, et al. 1995 [42] 
Blazeby JM, et al. 2004 [43]
Stages I and II (surgery) 0.65 
Stage III (chemo radiotherapy) 
0.4 
Stage IV (palliative care) 0.5
No values for population 
No values for premalignant 
gastric conditions
Gupta, 2011 [30] 
USA
Endoscopy + Barrett’s 
surveillance or 
Endoscopy
Inadomi JM, et al. 2003 [44] 
Rubenstein JH, et al. 2007 
[45] 
Inadomi JM, et al. 2009 [46]
Cancer 0.5-0.75 
Post-gastrectomy state 0.97 
(0.8-1)
No values for population 
No values for premalignant 
gastric conditions 
Value for cancer as a whole
Zhou, 2011 [34] China Serum pepsinogens + 
Endoscopy 
World Health Organization 
QoL (WHOQOL)- BREF 
questionnaire [47]
Healthy residents 1.00 
Gastric cancer patients 0.68-
0.66
Normal is 1 
No values for premalignant 
gastric conditions 
Just one value for gastric cancer
Dinis-Ribeiro, 2007 [29] 
Portugal
Yearly magnication 
chromoendoscopy + 
Serum Pepsinogens
Kaptein AA, et al. 2005 [48] Death 0
Chemotherapy 0.1–0.3 
Surgery 0.4–0.8 
Mucosectomy 0.8–0.95
No values for population 
No values for premalignant 
gastric conditions
Yeh, 2010 [36] USA Endoscopic surveillance 
every 1, 5 or 10 years
Hanmer J, et al. 2006 [49] 
Gold MR, et al. 1998 [25]
Age-related quality weight 
0.78-0.93 
Gastric cancer 0.49 (0.17-0.79)
No values for population 
No values for premalignant 
gastric conditions 
Just one value for gastric cancer
Legend: UBT: Urea Breath Test; Ag: Antigen.
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Advantages of this study is that it includes patients on a 
nationwide basis, from general and teaching hospitals, and 
oncology centers, it covers more than 1400 reports, providing 
more than 100 patients in each subgroup (no lesions vs. 
premalignant lesions vs. gastric cancer) and utilities are 
linked to a medical diagnosis conrmed by a doctor aer 
performing an endoscopy with biopsies when needed. In 
addition, by including a range of upper gastrointestinal diseases 
it means that utilities of the general population with the same 
background are comparable.
To prevent selection bias as possible, a variety of hospitals 
from all over the country were selected, participants were 
consecutive and unselected, no change in routine practice was 
necessary and the analysis of the results was blinded. Also, 
anxiety caused by endoscopy that could inuence the results 
in terms of utilities was consistently similar among groups.
When comparing our study results to the study by Gold 
et al used for the sample size calculation, utilities values in 
other diseases returned similar results to ours: for esophageal 
problems 0.70 vs. 0.69 and for peptic ulcer 0.66 vs. 0.62. Also, 
in a study performed in our country using the same EQ-5D 
questionnaire in gastrointestinal patients (n=125), utilities for 
gastric cancer (n=5) ranged between 50 and 70, including our 
result of 0.62 [27].
e nding of dierent utilities between male and female 
is in accordance with a similar study in Portugal and also in 
other countries, conrming that this consistent result should 
be incorporated in cost-utility models [19, 28]. 
e relevance of the present study to the already available 
literature comes from the existence of several problems within 
the methodology of cost-utility studies published. We think 
these problems might have been overcome with the present 
study (see Table III) [25, 29-49]. Xie et al, Dan et al, Gupta 
et al, Zhou et al, Dinis-Ribeiro et al did not use values for the 
asymptomatic population; Xie et al and Zhou et al used 1 as 
the value for the normal population; only Yeh et al had values 
for premalignant gastric conditions; only Dinis-Ribeiro et al 
had values for the post mucosectomy stage; only Dan et al and 
Dinis-Ribeiro et al presented more than a single value for all 
gastric cancer patients, irrespective of the type of treatment 
performed and only two authors used a single reference to 
obtain the utilities for their models: the study by Wang Q et al 
that is in Chinese and not available to most clinicians, and the 
study by Dinis-Ribeiro et al that used a systematic review of 
studies embracing several dierent questionnaires on patients 
with diagnosed or treated gastric cancer. Finally, not a single 
model evaluated dierently the male and female  utilities.
We think that it is very important to use a single validated 
instrument for all stages of disease so that utilities among 
dierent stages are not overestimated by the use of dierent 
and not comparable questionnaires. Also, as suggested by the 
guidelines, utilities valuation should come from community 
preferences as ours did and not only from diseased patients 
[4].
The results of our study have implications on the 
interpretation of previous models on endoscopic surveillance 
of gastric premalignant conditions because the wider utilities’ 
values used by others could result from using different 
questionnaires for different clinical situations, thereby 
overestimating dierences in utilities and the nal model 
outcome between strategies.
is study has some limitations that need to be addressed: 
in one hospital the questionnaires were completed after 
performing upper endoscopy while in all the others this was 
done before the examination and, although it is expected 
that answers to items such as mobility, self-care, usual 
activities and pain or discomfort are not inuenced by the 
examination, the item on anxiety might be inuenced by 
whether the questionnaire was completed before or aer the 
endoscopy. Also, in the absence of standard health values for 
the Portuguese population for the validated questionnaire 
used (EQ-5D-5L) we used values for the Spanish population. 
Although the populations are dierent and their valuation 
of QoL will be dissimilar, the closest possible proximity and 
geographic location should provide some degree of similarity.
CONCLUSIONS
Our results conrm the applicability of using a single 
standardized instrument such as EQ-5D-5L for all stages of 
disease as it captures dierences in utilities among stages and 
gender and wider dierences among stages reported in previous 
models might result from the use of dierent instruments and 
overestimate real dissimilarities. ese conclusions may be 
relevant to further cost-utility analysis in gastric cancer and 
should be incorporated by authors in their models. 
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